EnClear Therapies is First Place Winner of Massachusetts Medical Device Development Center $200K Challenge

— EnClear Wins Massachusetts Life Sciences Center Award —

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear
Therapies, a biotechnology company developing device-based therapies
for the treatment of neurodegenerative disease, today announced that the
company was named one of five first place winners of the eighth annual
Massachusetts Medical Device Development (M2D2) Center $200K Challenge.
The Massachusetts Medical Device Development Center is a lifeline for
the state’s smaller medical device companies, offering inventors and
executives easy, affordable and coordinated access to world-class
researchers and resources at the UMass
Lowell and the UMass
Medical School campuses of the University of Massachusetts.

“The M2D2 $200K Challenge has become emblematic of the rich culture of
medical device innovation in the Massachusetts biotech cluster and in
the UMass system,” said Mary Ann Picard, M2D2’s director of operations.
“EnClear’s novel approach to treating neurological diseases highlights
the high level of scientific and medical creativity we saw in this
year’s competition and the tremendous potential for improving the lives
of patients we see in each year’s submissions.”

EnClear’s winning pitch by Kevin Kalish, vice president of research and
development, described the company’s device-based system to halt the
progression of neurodegenerative diseases by removing toxic proteins
known to drive pathology. The system continuously recirculates
cerebrospinal fluids (CSF) and targets and removes toxic proteins from
CSF.

“We are tremendously honored to be selected from over 150 entrants as
the winner of the Massachusetts Life Sciences Award in the M2D2 $200K
Challenge,” said Anthony DePasqua, chief executive officer and
co-founder, EnClear Therapies. “Kevin’s presentation captured the
potential of our unique device in treating a variety of neurological
diseases such as Amyotrophic Lateral Sclerosis and progressive
Supranuclear Palsy for which there are currently no effective treatment
options. This award will support and hopefully accelerate our
development program with the goal of treating patients living with these
devastating conditions.”

Entries were analyzed based on value, strength and execution plan:

• Value – product, customer validation, business model and health care
  economics, competition, IP, market opportunity and patient benefit
• Strength – team strength, development plan, responsiveness/coachable,
  freedom to operate, regulatory and clinical burden, funding to date,
  resources needed
• Execution plan – stage of development, evidence, time to market,
  traction, partnerships and relationships, time to key milestones,
  upcoming funding.

The winners of the challenge were selected from 21 finalists who were
selected to give a live, four-minute pitch with one minute to answer
questions from the expert judges.

About EnClear Therapies

EnClear Therapies is a Cambridge (USA) based biotechnology company
developing neurology-focused, device-based systems that remove toxic
proteins as therapies for the treatment of neurodegenerative diseases
and provide closed loop delivery & monitoring of cerebrospinal fluids
(CSF). The company’s first products will target improving the lives of
patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive
Supranuclear Palsy (PSP). https://www.encleartherapies.com.

Contacts

Rob Kloppenburg
Shoreline Biotech Communications
617-930-5595